Regulatory Update · Updated July 2026
FDA Compounded Semaglutide Rules 2026: Everything That Changed
The FDA has fundamentally reshaped the compounded GLP-1 landscape over the past two years. Here's the full timeline, what each change means for patients, and what's still on the table.
The Timeline: 2022 to 2026
2022 — Surging demand for Ozempic and Mounjaro creates nationwide shortages. Both semaglutide and tirzepatide are placed on the FDA's drug shortage list, opening the door for compounding pharmacies to legally produce these medications at scale. Compounded GLP-1 products begin flooding the market at $150 to $300 per month, a fraction of brand-name pricing.
December 2024 — The FDA resolves the tirzepatide shortage, removing it from the shortage list. This triggers a wind-down period for 503B outsourcing facilities compounding tirzepatide, with a 90-day enforcement deadline set for March 2025.
February 2025 — The FDA resolves the semaglutide shortage, removing it from the shortage list. A similar 90-day wind-down period is set, with enforcement beginning by May 2025. Compounding of "essentially a copy" of branded semaglutide is no longer permitted for 503A or 503B entities.
Early 2025 — The Outsourcing Facilities Association files federal lawsuits challenging both shortage determinations. Courts deny preliminary injunctions, and the enforcement deadlines hold. Multiple court rulings create a complex but generally FDA-favorable legal landscape.
March 2026 — Hims & Hers Health exits compounded GLP-1 marketing following settlement with Novo Nordisk, removing one of the largest telehealth platforms from the compounded semaglutide market.
April 30, 2026 — The FDA proposes formally excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. If finalized, this rule would permanently bar 503B outsourcing facilities from compounding these drugs from bulk substances, regardless of future shortage status.
June 2026 — Public comment period on the proposed 503B exclusion closes, with over 4,200 comments submitted. A final rule could follow within months.
What's Banned vs What's Still Allowed
No Longer Permitted
503B outsourcing facilities producing batch quantities of semaglutide or tirzepatide that are "essentially a copy" of FDA-approved products. This includes large-scale compounding operations that were supplying telehealth platforms with mass-produced compounded GLP-1 medications. The shortage list pathway is closed, and the 503B Bulks List pathway is proposed for permanent closure.
Still Permitted
503A state-licensed pharmacies compounding patient-specific prescriptions for individual patients. This pathway operates under a different legal framework that doesn't depend on shortage list status. Some 503B facilities continue to compound under court injunctions or through combination formulations (such as semaglutide combined with vitamin B12) that may fall outside the "essentially a copy" restriction, though this area remains legally contested.
Find Providers Operating Under Compliant Pathways
Compare telehealth platforms using licensed 503A compounding pharmacies.
View Compliant Providers →The Safety Data Driving FDA's Position
The FDA's enforcement posture is backed by adverse event data. As of May 2026, the agency had received 990 adverse event reports associated with compounded semaglutide and over 730 associated with compounded tirzepatide. The FDA notes that many of these events are consistent with known side effects of the approved drugs, but reports of dosing errors from multi-dose vials — some requiring hospitalization — and counterfeit products with fraudulent labels have reinforced the agency's enforcement focus.
The FDA has also issued warning letters to companies selling unapproved products containing semaglutide or tirzepatide labeled "for research purposes" or "not for human consumption," which were being sold directly to consumers with dosing instructions.
What Happens Next
The most immediate regulatory event on the horizon is the finalization of the 503B Bulks List exclusion. With the public comment period closed, the FDA could issue a final rule within months. If finalized, the rule would permanently close the 503B compounding pathway for semaglutide, tirzepatide, and liraglutide.
Separately, the FDA has scheduled a July 2026 advisory committee meeting to consider adding certain peptide active ingredients — not currently found in FDA-approved drugs — to the bulk substances list. This could open new compounding pathways for related but distinct weight management compounds.
For patients currently accessing compounded GLP-1 medications, the practical takeaway is straightforward: the 503A patient-specific pathway remains the most stable option. If your provider works with a licensed 503A pharmacy and you have a valid prescription, your access is on solid legal ground — even as the broader regulatory landscape continues to tighten around 503B operations.
Stay Informed on GLP-1 Regulatory Changes
Explore current options from compliant providers.
Explore Current Options →This article is for informational purposes only and does not constitute medical or legal advice. Regulatory status of compounded GLP-1 medications changes frequently. Verify current regulations with the FDA and your prescribing provider. Information current as of July 2026.